| __timestamp | Blueprint Medicines Corporation | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 1244910 |
| Thursday, January 1, 2015 | 14456000 | 5029636 |
| Friday, January 1, 2016 | 19218000 | 4846776 |
| Sunday, January 1, 2017 | 27986000 | 5329003 |
| Monday, January 1, 2018 | 47928000 | 7121000 |
| Tuesday, January 1, 2019 | 96388000 | 9128000 |
| Wednesday, January 1, 2020 | 157743000 | 10731000 |
| Friday, January 1, 2021 | 195293000 | 10701000 |
| Saturday, January 1, 2022 | 237374000 | 16121000 |
| Sunday, January 1, 2023 | 295141000 | 37021000 |
| Monday, January 1, 2024 | 359272000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational expenses is crucial for success. Blueprint Medicines Corporation and Viking Therapeutics, Inc. offer a fascinating study in contrasts. Over the past decade, Blueprint Medicines has seen its Selling, General, and Administrative (SG&A) expenses skyrocket by nearly 3,600%, from $7.9 million in 2014 to $295 million in 2023. This reflects their aggressive expansion and investment in growth. Meanwhile, Viking Therapeutics has maintained a more conservative trajectory, with SG&A expenses increasing by approximately 2,900% over the same period, reaching $37 million in 2023. This strategic restraint may indicate a focus on lean operations. As these companies navigate the biotech landscape, their differing approaches to SG&A efficiency highlight the diverse strategies within the industry. Investors and analysts should consider these trends when evaluating potential growth and sustainability.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Insmed Incorporated or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs MannKind Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Xencor, Inc.